Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127714491 | 12771449 | 1 | I | 201609 | 0 | 20160920 | 20160920 | DIR | FDA-CTU | 24.00 | YR | M | N | 0.00000 | 20160920 | N | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127714491 | 12771449 | 1 | PS | CIMZIA | CERTOLIZUMAB PEGOL | 1 | Subcutaneous | TWO SYRINGES WEEKS 0,2,4 SUBCUTANEOUS | D | D | 901158 | 20170331 | 0 | 2 | DF | ||||
| 127714491 | 12771449 | 3 | C | CORTIFOAM AER | 2 | 0 | |||||||||||||
| 127714491 | 12771449 | 5 | C | LIDOCAINE. | LIDOCAINE | 1 | 0 | ||||||||||||
| 127714491 | 12771449 | 7 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
| 127714491 | 12771449 | 9 | C | MESELAMINE | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127714491 | 12771449 | 1 | Crohn's disease |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127714491 | 12771449 | Condition aggravated |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 127714491 | 12771449 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127714491 | 12771449 | 1 | 20160715 | 0 |